Chen Qi-Yin, Chaturvedi Pravin R, Luesch Hendrik
Department of Medicinal Chemistry, University of Florida, Gainesville, Florida, USA.
Center for Natural Products, Drug Discovery and Development (CNPD3), University of Florida, Gainesville, Florida, USA.
Org Process Res Dev. 2018 Feb 16;22(2):190-199. doi: 10.1021/acs.oprd.7b00352. Epub 2018 Jan 30.
Herein we describe the research and development of the process for the scale-up total synthesis of largazole, a potent class I selective histone deacetylase (HDAC) inhibitor, a potential anticancer agent and also useful for the treatment of other disorders where transcriptional reprogramming might be beneficial. The synthetic route and conditions for each fragment and final product were modified and optimized to make them suitable for larger scale synthesis. With the process we developed, hundreds of grams of each fragment and decagrams of final productlargazole were synthesized in good to excellent yields. The final target largazole was obtained in 21% overall yield over eight steps based on the longest sequence with over 95% HPLC purity.
在此,我们描述了一种用于大规模全合成拉戈唑(largazole)的工艺的研发过程。拉戈唑是一种强效的I类选择性组蛋白脱乙酰酶(HDAC)抑制剂,是一种潜在的抗癌药物,也可用于治疗其他可能受益于转录重编程的疾病。对每个片段和最终产物的合成路线和条件进行了修改和优化,使其适合更大规模的合成。通过我们开发的工艺,以良好至优异的产率合成了数百克的每个片段和数克的最终产物拉戈唑。基于最长序列,经过八步反应,最终目标产物拉戈唑的总产率为21%,HPLC纯度超过95%。